UroGen Pharma (URGN) Cash from Operations (2017 - 2026)
UroGen Pharma (URGN) posted quarterly Cash from Operations of 45316000.0 for Q1 2026, down 7.83% year-on-year from 49167602.6 in Q1 2025, and down 18.24% on a QoQ basis from 38325000.0 in Q4 2025.
UroGen Pharma (URGN) Cash from Operations (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported Cash from Operations for 10 consecutive years, with 45316000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Operations fell 7.83% year-over-year to 45316000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 165736000.0 (down 54.81% YoY) and the FY2025 annual result came in at 162444000.0, down 67.87% from the prior year.
- Cash from Operations fell to 45316000.0 in Q1 2026 per URGN's latest filing, from 38325000.0 in the prior quarter.
- Over the last five years, Cash from Operations for URGN reached as high as 12996000.0 in Q4 2023 and fell as low as 45316000.0 in Q1 2026.
- A 5-year average of 27556529.41 and a median of 24199000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 40.25% — and 2025, when it plunged 181.41%.
- Year by year, Cash from Operations stood at 21752000.0 in 2022, then soared by 40.25% to 12996000.0 in 2023, then slipped by 4.79% to 13619000.0 in 2024, then tumbled by 181.41% to 38325000.0 in 2025, then slipped by 18.24% to 45316000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 45316000.0, 38325000.0, and 42270000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | -45.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.32 Mn |
| Mar 31, 2026 | -45.32 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Sep 30, 2025 | -42.27 Mn |
| Sep 30, 2025 | -42.27 Mn |
| Jun 30, 2025 | -39.83 Mn |
| Jun 30, 2025 | -39.83 Mn |
| Mar 31, 2025 | -42.02 Mn |
| Mar 31, 2025 | -42.02 Mn |
| Dec 31, 2024 | -13.62 Mn |
| Dec 31, 2024 | -13.62 Mn |
| Sep 30, 2024 | -27.66 Mn |
| Sep 30, 2024 | -27.66 Mn |
| Jun 30, 2024 | -23.75 Mn |
| Jun 30, 2024 | -23.75 Mn |
| Mar 31, 2024 | -31.74 Mn |
| Mar 31, 2024 | -31.74 Mn |
| Dec 31, 2023 | -13.00 Mn |
| Dec 31, 2023 | -13.00 Mn |